



Industry Day Event Agenda October 29th-30th, 2024

Scan the QR code below for a digital copy of the agenda:



Tuesday, October 29th: Biopharmaceutical Manufacturing Innovations

8:00 AM - 9:15 AM: Registration and Networking Breakfast

- Welcome coffee and light refreshments
- Networking opportunities with industry peers, Posters available all day

9:15 AM - 9:25 AM: Opening Remarks

- Josh Marion, BioMaP-Consortium Program Manager, Advanced Technology International

9:25 AM - 10:00 AM: Keynote Address

- Topic: "Innovations in Biopharmaceutical Manufacturing: Scaling Up for Global Health"
- Speaker: Chandresh Harjivan, Associate Director for Domestic Preparedness and Response to Pandemics and Biological Threats, Office of Pandemic Preparedness and Response Policy

10:00 AM - 11:00 AM: Fireside Chat with BioMaP-Consortium 2024 Awardees

- Moderator: Brooke Luck, PhD, BARDA BioMaP-Consortium Program Manager
- Christina Smolke, Antheia Bio
- Andrew Magyar, Capra BioSciences
- Kevin Webb, API Innovation Center

11:00 AM - 11:30 AM: Member Introductions

- Celltheon; Vulcan Bioworks; Sunflower Therapeutics PBC; KOMO Biosciences;

11:30 AM – 12:00 PM: Onshoring Domestic Manufacturing Capability

- Moderator: Jill Hamaker, Partner, CGCN
- Sarah Gilbert, Chief of Staff, Rep. Neal Dunn – Energy and Commerce Committee
- Melodie Ha, Senior Professional Staff Member Minority, House Select Committee on Strategic Competition between the U.S. and the Chinese Communist Party

12:00 PM - 1:00 PM: Working Lunch

12:30 PM - 1:00 PM: Reverse Networking

- Avid Bioservices*; ThermoFisher/PPD*; Resilience Government Services*; Evonik*; Corning*





1:00 PM - 2:00 PM: Panel Discussion: “Overcoming Challenges in Supply Chain and Manufacturing Scalability”

- Moderator: Sushma Savarala, Interdisciplinary Scientist, IBMSC
- Bob Huffman, Program Director, Manufacturability & Resilience, BARDA
- Christina Smolke, CEO & Co-Founder, Antheia Bio
- Lisa Roessler, Chief Commercial Officer, Amyris

2:00 PM - 3:00 PM: BARDA Programs Discussion: Lessons Learned from COVID Response

- Moderator: Justin Yang, Executive Liaison, BioMaP-Consortium
- Mike Stebbins, Senior Vice President, Medical and Threat Countermeasures Division, ATI
- David Simon, Director, Medical Countermeasures Preparedness and Response, BARDA
- Tim Belski, Program Director, Biopharmaceutical Manufacturing Preparedness, BARDA

3:00 PM - 3:30 PM: Member Introductions & Reverse Networking

- The United States Pharmacopeial Convention (USP); Innerspace; MustardSeed PMO; VGXI*; Donaldson*

3:30 PM - 4:30 PM: BioMaP-C Executive Steering Committee

- Mike Stebbins, Senior Vice President, Medical and Threat Countermeasures Division, ATI
- Peter Stolba, Vice President of Business Development, Halozyme
- Whitney Tull, Vice President of Government Affairs, STERIS
- David Powell, Vice President of Business Development & Government Affairs, Grand River Aseptic Manufacturing
- Melissa Berquist, Technical Head and Director of Commercial Development, Resilience
- Flavia D’Souza, Co-Founder & Head of Quality, Sentio BioSciences
- Helen Bush, Director of Supply Chain, Evonik
- Sean Kirk, Principal, Arena BioPharma Consulting
- John Clapham, Chief Executive Officer, BioTechnique

4:30 PM - 6:30 PM: Networking Reception

- Networking reception with cash bar and appetizers

BioMaP-Consortium At-A-Glance:

Who We Are:

The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) supports the Biomedical Advanced Research and Development Authority (BARDA) and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of required raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services.

What We Do:

The BioMaP-Consortium seeks to expand the industrial and manufacturing base for medical countermeasures to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to meet the nation’s public health preparedness and response requirements.



Wednesday, October 30th: Preparing for Current and Future Health Emergencies

8:00 AM - 9:00 AM: Networking Breakfast sponsored by API Innovation Center

- Welcome coffee and breakfast
- Networking opportunities with industry peers
- Posters available all day

9:00 AM - 9:30 AM: Keynote Address

- Topic: "Global Health Security: The Role of Biopharma in Future Pandemics"
- Speaker: Ashish Jha, Dean, School of Public Health, Brown University

9:30 AM - 10:00 AM: Reverse Networking

- ApiJect*; Amneal Pharmaceuticals of New York*; Jubilant HollisterStier*; Ocugen*; Walmart*

10:00 AM – 10:10 AM: Transition to First ESC Breakout Session

10:10 AM - 10:55 AM: ESC Breakout Session #1

- Critical Infrastructure
 - o Justin Yang, Executive Liaison, BioMaP-Consortium, ** on behalf of Peter Stolba, Vice President of Business Development, Halozyme*
- Sterilization
 - o Whitney Tull, Vice President of Government Affairs, STERIS
- DS Manufacturing
 - o Melissa Berquist, Technical Head and Director of Commercial Development, Resilience
- Delivery Devices
 - o Jayanand Vasudevan, BARDA ASPR **on behalf of David Powell, Vice President of Business Development & Government Affairs, Grand River Aseptic Manufacturing*

10:55 AM – 11:00 AM: Transition to Second ESC Breakout Session

Today's Networking Breakfast Sponsored By:



The **API Innovation Center (APIIC)** is a 501(c)(3) nonprofit public benefit organization headquartered in St. Louis, Missouri, dedicated to driving health security and economic growth for the nation and its citizens through U.S.-based production of critical medicines. Through investments in and collaboration across the pharmaceutical supply chain, APIIC coordinates with its established partner network to advance novel technology, optimize existing facilities, manufacture critical ingredients, and reshore the production of vulnerable medications to the U.S. In September, the Biden-Harris Administration, through the Administration for Strategic Preparedness and Response (ASPR), awarded APIIC with approximately \$14 million in funding under the Defense Production Act Title III to bolster U.S. pharmaceutical manufacturing. Learn more at <https://apicenter.org/>



11:00 AM - 11:45 AM: ESC Breakout Session #2

- Enabling Platforms
 - o Flavia D'Souza, Co-Founder & Head of Quality, Sentio BioSciences
- Logistics & Supply Chain
 - o Helen Bush, Director of Supply Chain, Evonik
- Commercial Scale Manufacturing
 - o Sean Kirk, Principal, Arena BioPharma Consulting
- Drug Product & Fill/Finish
 - o John Clapham, Chief Executive Officer, BioTechnique

11:45 AM - 11:55 AM: Transition time to reconvene in Main Ballroom

11:55 AM - 12:15 PM: BARDA Contracting & Working with the Government

- Rebecca Harmon, Director of Contracts, Advanced Technology International

12:15 PM - 1:15 PM: Lunch Break

1:15 PM - 1:45 PM: Member Introductions

- CONTINUUS Pharmaceuticals; Qoolabs, Inc.; Amyris; BioFactura; Watson-Marlow Fluid Technology Group

1:45 PM - 2:45 PM: Panel Discussion: Regulatory Innovation

- Topic: "Regulatory Pathways and Public-Private Partnerships in Health Emergencies"
- Moderator: Kerrie DeMarco, Chief Technology Advisor, BioMaP-Consortium
- Jeremiah Kelly, Venable
- Danielle Turley, BARDA RQA
- Enlli Lewis, 1 Day Sooner

2:45 PM - 2:50 PM: Closing Remarks & Farewell

- Summary of key takeaways

2:50 PM - 3:00 PM: Transition & Setup for Matchmaking

3:00 PM - 4:45 PM: 1-on-1 Matchmaking Session

- Matchmaking Hosts are identified with an asterisk (*) throughout the agenda.

Thank you to all participants!

The background of the bottom half of the page is a blurred image of a laboratory or pharmaceutical manufacturing facility. It shows various pieces of equipment, including what looks like a robotic arm, glass vials, and other lab equipment. The image is in a light blue and white color scheme, matching the overall theme of the document.



Poster Presentations

Posters will be available all day, on Oct. 29th and 30th, in the Regency Foyer reception area.

- **Celltheon** - *Rapid Response Biomanufacturing: OmniCHO's Two-Week GMP Protein Solution*
- **VGXI, Inc.** - *Business and Technical Capabilities of VGXI*
- **Ocugen, Inc.** - *Next Generation Mucosal Vaccines for Respiratory Viruses Based on Inhalation Technology*
- **Donaldson** - *Accelerating development of gene therapies through truly scalable technologies*
- **Orexo AB** - *amorphOX® - an amorphous powder- based platform to develop highly stable products, such as vaccine*
- **Global Key Solutions Corp.** - *Using Regulatory Data to Enhance Compliance*
- **PSC Biotech** - *Fast-Tracking GMP Facility Qualification - Preparing for the Unknown*
- **Integrated Pharma** - *An Integrated Approach to Developing and Commercializing Novel Diagnostics and Therapeutics: A One-Stop Solution*
- **Donaldson** - *Reimagining purification of biotherapeutics using affinity liquid phase-separating IsoTag reagents*
- **Amyris, Inc.** - *Amyris innovates to profitably deliver clean molecules to the world*
- **CHO Plus** - *High Monoclonal Antibody Production in Fed-Batch Cultures by Engineered CHO Cells with Requisite Phenotypes*
- **Univercells Quantoom Bioscience** - *Seamless Scalable mRNA Production with Ntensify®*
- **Sublime LLC** - *Distributed, Continuous, Scalable, Green Particle Engineering Particle Engineering for Pharma*
- **Corning Life Sciences** - *Improving Fill and Finish Efficiency with a Drop-in Vial Solution*
- **Chromatan, Inc.** - *New hyper-efficient vision for mRNA production facility of the future - a fully steady state manufacturing process with integrated PAT*
- **Premas Technologies, Inci** - *Novel Thermo stable triple antigen VLP vaccines; rapid response and focus on influenza.*

